無料プレビュー

DexCom, Inc. (DXCM) · NASDAQ Global Select

プロフィール

Dexcom designs, develops and commercializes continuous glucose monitoring systems for diabetes and metabolic health management globally. The company offers the Dexcom G7 and G7 15 Day integrated CGM systems for prescription use, the over-the-counter Stelo biosensor for prediabetes and Type 2 diabetes without insulin, legacy G6 and ONE+ systems, plus remote monitoring and data platforms. Dexcom operates direct sales and distribution channels across North America, Europe, Asia Pacific, Latin America, Africa and the Middle East, serving patients, caregivers and clinicians with FDA-cleared and CE

主要指標

株価: $84.41 (+0.13%)
時価総額: 319億ドル
PER（今期予想）: 31.6
PBR: 12.4
配当利回り: —
52週レンジ: $54.11 – $92.59
業種: Healthcare / Medical - Devices
上場: NASDAQ Global Select
構成銘柄: S&P 500 0.05% · Nasdaq 100 0.13%

比較会社: ABT Abbott Laboratories、MDT Medtronic Plc、SYK Stryker Corporation、BSX Boston Scientific Corporation、EW Edwards Lifesciences Corporation、GEHC GE HealthCare Technologies Inc.、PHG Koninklijke Philips N.V.、ZBH Zimmer Biomet Holdings, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-29 · 更新: 2026-10-08